AIM: Monitoring of cardiotoxicity of conventional and high-dose chemotherapy (HD-CT) with multiple biomarkers of cardiac injury - glycogen phosphorylase BB (GPBB), heart-type fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. METHODS: A total of 47 adult acute leukemia patients were studied - 24 patients treated with conventional CT containing anthracyclines (ANT) and 23 patients treated with HD-CT (myeloablative preparative regimen) followed by hematopoietic cell transplantation (HCT). Cardiac biomarkers were assessed prior to treatment (before CT/HD-CT), after first CT with ANT, after last CT with ANT in the first group, after HD-CT and after HCT in the second group. Values above the reference range were considered elevated. RESULTS: Before CT/HD-CT, all biomarkers of cardiac injury were below the cut-offs in all patients. GPBB increased above the cut-off (7.30 microg/L) in 4 (16.7%) patients after first CT and in 5 (20.8%) patients after last CT with ANT. GPBB increased above the cut-off in 5 (21.7%) patients after HD-CT and remained elevated in 5 (21.7%) patients after HCT. CTnI became elevated (above 0.40 microg/L) in 2 (8.3%) patients after first and last CT with ANT. Both patients with cTnI positivity had elevated GPBB. Other tested biomarkers remained below the cut-offs during the study. CONCLUSION: Our results suggest that GPBB could become a sensitive biomarker for detection of acute cardiotoxicity associated with conventional CT containing ANT and HD-CT followed by HCT. The predictive value for development of cardiomyopathy in the future is not known and should be evaluated during a prospective follow-up. Based on our data, a larger prospective and multicenter study would be most desirable to define the potential role of new circulating biomarkers in the assessment of cardiotoxicity in oncology.

Department of Medicine 2 Clinical Hematology University Hospital and Charles University Faculty of Medicine in Hradec Kralove Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12026171

003      

CZ-PrNML

005      

20121207102134.0

007      

ta

008      

120817s2010 un f 000 0#eng||

009      

AR

035    __

$a (PubMed)20693970

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a un

100    1_

$a Horacek, J M $u Department of Medicine II - Clinical Hematology, University Hospital and Charles University, Faculty of Medicine in Hradec Kralove, Czech Republic. jan.hor@post.cz

245    14

$a The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia / $c JM. Horacek, M. Vasatova, M. Tichy, R. Pudil, L. Jebavy, J. Maly,

520    9_

$a AIM: Monitoring of cardiotoxicity of conventional and high-dose chemotherapy (HD-CT) with multiple biomarkers of cardiac injury - glycogen phosphorylase BB (GPBB), heart-type fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. METHODS: A total of 47 adult acute leukemia patients were studied - 24 patients treated with conventional CT containing anthracyclines (ANT) and 23 patients treated with HD-CT (myeloablative preparative regimen) followed by hematopoietic cell transplantation (HCT). Cardiac biomarkers were assessed prior to treatment (before CT/HD-CT), after first CT with ANT, after last CT with ANT in the first group, after HD-CT and after HCT in the second group. Values above the reference range were considered elevated. RESULTS: Before CT/HD-CT, all biomarkers of cardiac injury were below the cut-offs in all patients. GPBB increased above the cut-off (7.30 microg/L) in 4 (16.7%) patients after first CT and in 5 (20.8%) patients after last CT with ANT. GPBB increased above the cut-off in 5 (21.7%) patients after HD-CT and remained elevated in 5 (21.7%) patients after HCT. CTnI became elevated (above 0.40 microg/L) in 2 (8.3%) patients after first and last CT with ANT. Both patients with cTnI positivity had elevated GPBB. Other tested biomarkers remained below the cut-offs during the study. CONCLUSION: Our results suggest that GPBB could become a sensitive biomarker for detection of acute cardiotoxicity associated with conventional CT containing ANT and HD-CT followed by HCT. The predictive value for development of cardiomyopathy in the future is not known and should be evaluated during a prospective follow-up. Based on our data, a larger prospective and multicenter study would be most desirable to define the potential role of new circulating biomarkers in the assessment of cardiotoxicity in oncology.

650    _2

$a dospělí $7 D000328

650    _2

$a antitumorózní látky $x aplikace a dávkování $x škodlivé účinky $7 D000970

650    _2

$a kreatinkinasa, forma MB $x krev $7 D052279

650    _2

$a proteiny vázající mastné kyseliny $x krev $7 D050556

650    _2

$a glykogenfosforylasa $x krev $7 D024981

650    _2

$a srdce $x účinky léků $7 D006321

650    _2

$a transplantace hematopoetických kmenových buněk $7 D018380

650    _2

$a lidé $7 D006801

650    _2

$a akutní myeloidní leukemie $x krev $x farmakoterapie $x chirurgie $7 D015470

650    _2

$a myoglobin $x krev $7 D009211

650    _2

$a troponin I $x krev $7 D019210

650    _2

$a troponin T $x krev $7 D020107

650    _2

$a nádorové biomarkery $x krev $7 D014408

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Vasatova, M

700    1_

$a Tichy, M

700    1_

$a Pudil, R

700    1_

$a Jebavy, L

700    1_

$a Maly, J

773    0_

$w MED00174402 $t Experimental oncology $x 1812-9269 $g Roč. 32, č. 2 (2010), s. 97-9

856    41

$u https://pubmed.ncbi.nlm.nih.gov/20693970 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y m

990    __

$a 20120817 $b ABA008

991    __

$a 20121207102208 $b ABA008

999    __

$a ok $b bmc $g 948213 $s 783517

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2010 $b 32 $c 2 $d 97-9 $i 1812-9269 $m Experimental oncology $n Exp Oncol $x MED00174402

LZP    __

$a Pubmed-20120817/10/04